ADVERTISEMENT

Torrent Pharma Q2 Results Review - Strong Performance Across Branded Markets: Nirmal Bang

We maintain 'Buy' with a target price of Rs 2,197, valuing it at 19 times September 25E enterprise value/Ebitda

<div class="paragraphs"><p>India's pharmaceutical market reported a double-digit growth for the second straight month, but on a low base. (Source: Unsplash)</p></div>
India's pharmaceutical market reported a double-digit growth for the second straight month, but on a low base. (Source: Unsplash)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit